BEND, Ore., April 7, 2011 /PRNewswire/ -- Bend Research Inc. (www.bendres.com), a leading independent drug-formulation development and manufacturing company, announced that it has received a new U.S. patent covering the use of polymer additives to improve and sustain the bioavailability of low-solubility drugs in the human body.
The patent protects formulations that enhance the absorption of low-solubility drugs by blending the drug with an additive, resulting in improved bioavailability. There is a growing need for this technology, since it is estimated that more than 40% of drugs in development have low aqueous solubility. Use of these polymer additives means lower drug doses can be used to achieve better therapies for these drugs. The technology works by sustaining high concentrations of drug in the gastrointestinal tract.
"This technology is on target with our mission of advancing our clients' best new medicines," said Bend Research President and CEO Rod Ray. "It provides one more way we can help our customers provide novel therapies to treat illnesses that desperately need new approaches."
"Pharmaceutical industry leaders acknowledge that discovering and bringing these new compounds forward is very complicated," Ray observed, "and Bend Research scientists and engineers are well known for providing key assistance to leading pharmaceutical companies facing this challenge."
The patent covers blending solubility-improved drug forms with solubility-enhancing polymer additives. Drug forms covered by the patent are nanoparticles, absorbed drugs, drugs in nanosuspensions, supercooled drug melts, cyclodextrin/drug forms, gelatin dosage forms, and soft-gel dosage forms. Often, such drug forms dissolve rapidly in the GI tract and then precipitate to low-solubility forms before they can be absorbed. Blending these drug forms with a solubility-enhancing polymer provides a simp